Events

  • Digital Health: Catapulting Personalised Medicine Forward

Digital Health: Catapulting Personalised Medicine Forward

27th November, 2014 - Connected Digital Economy Catapult, London


This round table will feature demonstrations of how next-generation technologies and social media will integrate with public health, thus facilitating the burgeoning market for personalised medicines. The session will include disruptive start-ups and technology savvy practitioners finding common ground in the desire to bring stratified medicines to patients.

This event is organised in collaboration with:

logoFPM CDE_LG_Colour_CMYK-3 DCC-Wordmark-Black-RGB
  • WEBINAR: What are Medicine’s Adaptive Pathway’s to Patients (MAPPs)?

WEBINAR: What are Medicine’s Adaptive Pathway’s to Patients (MAPPs)?

December 11th, 2pm - 3:30 PM CET

This webinar is by invitation only for the following participants: EFPIA, PhRMA, EBE and Vaccines Europe members. This webinar will update EFPIA members on Medicines Adaptive Pathways to Patients (MAPPs) and its potential impact on research, development, licensing, HTA, and pricing & reimbursement in relation to early patient access.

News

  • Independent report points the way forward for the responsible sharing of clinical trial data

Independent report points the way forward for the responsible sharing of clinical trial data

  • January 15th, 2015
A new culture is needed to promote the equitable and open sharing of data, to advance science, whilst protecting the interests of all stakeholders, says the US Institute of Medicine
The sharing of clinical trials data is clearly in the public interest, but huge effort is required to develop the policies and put in place the technical infrastructure and create a culture of openness, according to a new report from the US Institute of Medicine (IOM).
  • Conference Report: Digital Health – Catapulting Personalised Medicine Forward

Conference Report: Digital Health – Catapulting Personalised Medicine Forward

  • December 12th, 2014
In a ground-breaking collaboration, The UK’s Digital Catapult, The Fellowship of Post Graduate Medicine, IDEALondon, and Vital Transformation brought together the best and brightest minds in Europe working at the frontiers of research where Personalised Medicines and Health Technologies intersect. This round table demonstrated how next-generation technologies and social media will integrate with public health, thus facilitating the burgeoning market for personalised medicines. The sessions included disruptive start-ups and technology savvy practitioners finding common ground in the desire to bring stratified medicines to patients.
  • TEMPEST mHealth : mHealth in 28 EU Member States

TEMPEST mHealth : mHealth in 28 EU Member States

  • November 3rd, 2014
One of the biggest health care challenges in the coming years is how technology can be used to improve health service delivery. With the steadily increasing average life expectancy across all of Europe expected to be over 80 by 2025 and 82.5 by 2050, new and improved processes need to be delivered to meet future health requirements.
  • Conference Report: Better Science, Better Health: New Trial Pathways and Better Patient Data

Conference Report: Better Science, Better Health: New Trial Pathways and Better Patient Data

  • October 31st, 2014
CONFERENCE REPORT: On October 21st, an international group of experts was invited to the Royal College of Physicians in London to discuss how new clinical regulatory pathways, sources of evidence, and evolving data on real world patients can be used both to expedite the development of drugs and improve their quality and access. Broadly called “MAPPs” (Medicines Adaptive Pathways to Patients), the goal is to speed patient access to needed therapies while increasing the productivity of industry R&D spending.
  • Weighing patients’ understanding of risk

Weighing patients’ understanding of risk

  • June 11th, 2014
Patients can bring unique insights to the medicines approval process. But how can regulators use patient preferences to inform decisions on innovative medicines?